← Human Trials & Peer-Reviewed Studies
Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT study.
Plain-language guide to PMID 42032273 (2026): open-label randomized controlled trial of Angiotensin II in 2 patients.
Key Facts
- PMID
- 42032273
- Journal
- Hypertension research : official journal of the Japanese Society of Hypertension
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Kario K et al. (22 authors)
- DOI
- 10.1038/s41440-026-02634-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this randomized controlled trial publication.
Mineralocorticoid receptor blockers (MRBs) are positioned as second-line antihypertensive agents in the 2025 Japanese Society of Hypertension guidelines, yet evidence in older patients remains limited.
Who Took Part
The abstract describes 2 patients taking part.
By PubMed's age tags, the people studied were older adults and people over 80, both men and women.
How the Study Was Run
The researchers set it up as a randomized, open-label, multicenter and parallel-group study.
Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Angiotensin II study did not mask who received what.
Running at several centres spread the Angiotensin II study over different clinics and patient groups.
Groups ran in parallel: each of the patients stayed in one arm throughout.
What Was Measured
Topics PubMed links to this paper include Hypertension, Angiotensin Receptor Antagonists, Calcium Channel Blockers, Antihypertensive Agents, Pyrroles, Sulfones and Mineralocorticoid Receptor Antagonists.
Author keywords: Angiotensin II receptor blockers, Esaxerenone, Mineralocorticoid-receptor blockers, Morning hypertension and Randomized comparative study.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Angiotensin II in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2026 (Hypertension research : official journal of the Japanese Society of Hypertension), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.